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Background: The ATP-binding cassette (ABC) transporters P-glycoprotein (P-gp)/ABCB1 and breast cancer resistance
protein (BCRP)/ABCG2 are involved in the intestinal absorption and renal excretion of various substrate drugs. Their
activities affect sub-therapeutic drug concentrations and excretion of natural transporter substrates. The new oral
anti-HCV drug telaprevir has dramatically improved the efficacy of hepatitis-C virus (HCV) treatment, and recent
studies have suggested a possible pharmacological interaction between telaprevir and P-gp. We studied the kinetics
of in vitro interactions between telaprevir and P-gp and BCRP to understand the molecular basis of that interaction.
Findings: The effect of telaprevir on P-gp- and BCRP-mediated transport was evaluated by an in vitro vesicle transporter
assay using different transport substrates, and the kinetics of transporter inhibition was determined. The results showed
that telaprevir could inhibit P-gp- and BCRP-mediated transport in the in vitro vesicle transport assay, with each IC50
values of ≈ 7 μmol/L and ≈ 30 μmol/L, respectively. Analyses of Lineweaver–Burk plots showed that telaprevir was likely
to be a competitive inhibitor against P-gp and BCRP. Photoaffinity labeling experiments were employed to observe
competitive inhibition by telaprevir using iodoarylazidoprazosin (IAAP) as a binding substrate for P-gp and BCRP. These
experiments revealed that telaprevir inhibited [125I]-IAAP-binding with P-gp and BCRP.
Conclusion: Telaprevir competitively inhibited P-gp and BCRP, and P-gp-mediated transport was more sensitive to
telaprevir compared with BCRP-mediated transport. These data suggest that telaprevir represses the transporter
functions of P-gp and BCRP via direct inhibition.
Keywords: P-glycoprotein, Breast cancer resistance protein, Telaprevir, Inhibition, Transporter, Vesicle transporter assay,
Kinetics, [125I]-IAAP, HCV, Photoaffinity labelingBackground
Telaprevir is a new, orally-administered drug acting dir-
ectly against hepatitis-C virus (HCV) non-structural 3/4A
(NS3/4A) protease [1]. Combination of telaprevir, pegy-
lated interferon and ribavirin has been shown to increase
significantly the sustained virological response in patients
[2]. Antiviral chemotherapies for the HCV, hepatitis-B
virus (HBV) and human immunodeficiency virus (HIV)
comprise various drug combinations, so pharmacological
drug–drug interactions with members of the cytochrome
P-450 superfamily have been considered carefully [3]. With
regard to drug interactions with transporters, functional* Correspondence: noguchi-kj@pha.keio.ac.jp
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reproduction in any medium, provided the orinteractions between anti-HCV drugs and the ABC trans-
porter protein have become apparent [4,5]. Telaprevir is
reported to be a substrate and an inhibitor of P-gp, but
not of breast cancer resistance protein (BCRP) [6] (avail-
able at http://pi.vrtx.com/files/uspi_telaprevir.pdf; 2011);
however, the biochemical basis of such differences in
inhibition is incompletely understood. Moreover, under-
standing based on observations from clinical and cell-
based assays should include direct and indirect effects by
metabolic enzymes [7-9]. Therefore, studies on the direct
effects between drugs and transporters are necessary to
understand the mechanism of complicated drug–drug
interactions.
We have been studying various drug interactions with P-
gp and BCRP [10-16]. For example, verapamil and tyrosine
kinase inhibitors (TKIs) such as imatinib, gefitinib, andtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(FTC), certain flavonoids and the TKIs mentioned above
also inhibit BCRP-mediated transport. Our studies have
suggested that multiple binding sites on ABC transporter
proteins cause complicated differences in transporter inhib-
ition, depending on the substrate and inhibitor [15,17,18].
In the present study, we investigated the biochemical
basis of the in vitro interactions of P-gp and BCRP with
telaprevir. We analyzed their kinetics using in vitro cell-
free systems to provide mechanistic insights into the
interaction between ABC transporters and telaprevir.
Methods
Reagents
Telaprevir was purchased from Selleck Chemicals (Houston,
TX, USA). FTC was from Alexis (San Diego, CA, USA)
and verapamil was from Sigma–Aldrich (St. Louis, MO,
USA). [3H]-labeled vincristine (VCR), estrone 3-sulfate
(E1S), methotrexate (MTX), and [125I]-labeled iodoarylazi-
doprazosin (IAAP) were purchased from Perkin-Elmer
Life Sciences (Boston, MA, USA). All other reagents were
available commercially.
Intravesicular transport assay
Plasma membrane vesicles (22.5 μg of protein) were pre-
pared from K562/MDR and K562/BCRP cells as described
previously [13]. Then, they were mixed with [3H]-labeled
VCR (for P-gp) or E1S or MTX (for BCRP), and telaprevir
at the indicated concentration in the reaction buffer
(0.25 mol/L sucrose, 10 mmol/L HEPES-NaOH (pH 7.4),
10 mmol/L MgCl2, 10 mmol/L phosphocreatine, 100 μg/
mL creatine phosphokinase, with or without 3 mmol/L
adenosine triphosphate (ATP)) in a total volume of 50 μL.
After 10 min of incubation at 25°C, the reaction mixture
was stopped by the addition of ice-cold stop solutionFigure 1 Effect of telaprevir on the intravesicular transport of vincrist
telaprevir-absent or -present conditions was determined by measuring the
ver–Burk plots of inhibition of VCR uptake by P-gp. The VCR concentration
was 0, 1, 10, and 100 μmol/L (A) and 20 μmol/L (B), respectively. Membran
of VCR, telaprevir, and 3 mmol/L of ATP in the incubation medium as desc
(white column for ATP-absent; gray column for ATP-present) and K562⁄MD
and the inverse is shown for no inhibitor (open rhombus) and with telaprevir
(B) determinations.(0.25 mol/L sucrose, 10 mmol/L HEPES-NaOH (pH 7.4),
0.1 mol/L NaCl) and centrifuged at 18,000 × g for 10 min
at 4°C. The pellets were solubilized by a liquid scintillation
counter to measure their radioactivity levels. For kinetics
analyses, the Michaelis–Menten equation and Lineweaver–
Burk plots were applied to visualize the mechanism of
transport inhibition, as v =Vmax[S]/([S] + (1 + [I]/Ki)Km),
where [S] and [I] are concentrations of substrate and
inhibitor respectively, and v is velocity of substrate up-
take by transporter. The enzymatic values for Michaelis–
Menten constants of substrates (Km) and inhibitors (Ki)
and the maximum uptake rate for a transporter-mediated
process (Vmax) were calculated by estimating the slopes
(=Km(1 + [I]/Ki)/Vmax), x-intercepts (= − 1/(Km(1 + [I]/
Ki)) and y-intercepts (=1/Vmax) on the plots mentioned
above in competitive-inhibition mode. Competitive inhib-
ition causes different slopes and x-intercepts between the
two data, but with similar y-intercepts. Non-competitive
inhibition shows a similar x-intercept but different slopes
and y-intercepts. Uncompetitive inhibition shows simi-
lar slopes.
Photoaffinity labeling with IAAP
Photoaffinity labeling assay was done as described previ-
ously [13]. In brief, plasma membrane fractions (45 μg pro-
tein/sample) were pre-incubated at 4°C for 5 min at the
indicated concentration of telaprevir in 0.25 mol/L sucrose
solution containing 10 mmol/L HEPES-NaOH (pH 7.4).
Then, 5 nmol/L radioactive iodine-labeled IAAP, i.e., [125I]-
IAAP (2200 Ci/mmol), was added and the mixture incu-
bated for an additional 10 min. Samples were kept on ice
and illuminated with an ultraviolet lamp (B-100AP; UVP,
Upland, CA, USA) at 365 nm for 30 min. These pro-
cesses were carried out on ice. For the BCRP assay, the
labeled BCRP protein was solubilized in a bufferine sulfate (VCR) by P-gp. A. The ability to transport VCR in
radioactivity taken up in membrane vesicles. B. Analyses of Linewea-
was 100 nmol/L (A) and 50, 100, and 200 nmol/L (B), and of telaprevir
e vesicles from K562/MDR cells were mixed with each concentration
ribed in the Methods section. VCR uptake is shown for parental K562
R (dark-gray column for ATP-absent; black column for ATP-present) (A)
(black circle) (B). Results are means ± SD of triplicate (A) or quadruplicate
Table 1 Analyses of Lineweaver–Burk plots for P-gp
Vmax (pmol/mg/10 min) Ki (μmol/L)
No inhibitor With 20 μmol/L telaprevir
8.2 7.1 4.8
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NaCl, 1 mmol/L ethylenediamine tetra-acetic acid (EDTA))
and immunoprecipitated with anti-BCRP antibody BXP-
21 (Millipore, Billerica, MA, USA), then solubilized by
Laemmli sodium dodecyl sulfate (SDS) buffer. For the P-
gp assay, membrane fractions were solubilized directly by
Laemmli SDS buffer. Samples were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and gels were dried. The binding of [125I]-IAAP
with P-gp and BCRP was quantified using a FLA7000
Bioimage Analyzer (Fuji Film, Tokyo, Japan) and Multi-
Gauge software (Fuji Film).
Findings
Inhibition of P-gp and BCRP by telaprevir in vitro
The intravesicular transport assay was carried out to
analyze the kinetics of telaprevir inhibition on P-gp- and
BCRP-mediated transport in vitro.
Figure 1A shows that telaprevir inhibited ATP-dependent
[3H]-VCR transport in vitro in a dose-dependent manner.Figure 2 Effect of telaprevir on the intravesicular transport of estrone
telaprevir-absent or -present conditions was determined by measuring the
periment was done for MTX. B. Analyses of Lineweaver–Burk plots of inhib
L (A) and 50, 100, and 200 nmol/L (B), and of telaprevir was 0, 1, 10, and 1
100 nmol/L (A), and 100, 200 and 400 nmol/L (B). Membrane vesicles of K5
those shown in Figure 1.Analyses of Lineweaver–Burk plots showed that the inhibi-
tory mode of telaprevir for P-gp-mediated VCR transport
was competitive (Figure 1B). The calculated Vmax values
(pmol/mg/10 min) were 8.2 in the control condition and
7.1 in the presence of telaprevir (20 μmol/L). The cal-
culated Ki value of telaprevir on P-gp-mediated VCR
transport was 4.8 μmol/L (Table 1). These results sug-
gested that telaprevir acted as a competitive inhibitor for
P-gp-mediated VCR transport.
Inhibitory effect of telaprevir on BCRP-mediated
transport in vitro was also analyzed using two transport
substrates: E1S and MTX. Telaprevir inhibited [3H]-E1S
and [3H]-MTX transport in a dose-dependent manner
at comparable levels (Figure 2A). Analyses of Linewea-
ver–Burk plots showed that the inhibitory mode of tela-
previr for BCRP-mediated E1S and MTX transports
appeared to be competitive (Figure 2B). The calculated
Vmax values (pmol/mg/10 min) were 38 in the control
condition and 41 in the presence of telaprevir (50 μmol/L).
Similar analysis on BCRP-mediated MTX transport also
demonstrated that the calculated Vmax values (pmol/
mg/10 min) were 4.9 in the control condition and 4.6
in the presence of telaprevir (50 μmol/L). The calcu-
lated Ki value of telaprevir on BCRP-mediated E1S
transport was 44 μmol/L, and that on BCRP-mediated
MTX transport was 94.8 μmol/L; these findings suggested3-sulfate (E1S) and MTX by BCRP. A. The ability to transport E1S at
radioactivity of [3H]-E1S taken up in membrane vesicles. A similar ex-
ition of E1S and MTX uptake by BCRP. E1S concentration was 50 nmol/
00 μmol/L (A) and 50 μmol/L (B), respectively. MTX concentration was
62/BCRP cells were used. The procedures were almost identical to
Table 2 Analyses of Lineweaver–Burk plots for BCRP
Vmax (pmol/mg/10 min) Ki (μmol/L)
No inhibitor With 50 μmol/L telaprevir
E1S 37.5 41.2 44.4
MTX 4.9 4.6 94.8
Figure 3 Effect of telaprevir on photoaffinity labeling of P-gp
and BCRP with [125I]-IAAP. K562/MDR- or K562/BCRP-vesicles were
mixed with the indicated concentrations of telaprevir for 5 min.
Vesicles were pre-incubated with 5 nmol/L [125I]-IAAP (2200 Ci/mmol)
for 10 min, and then illuminated with a UV lamp (365 nm) for 30 min.
IAAP-labeled protein was solubilized by Laemmli SDS buffer directly
(for the P-gp assay) or after immunoprecipitation (for the BCRP assay),
and subjected to SDS-PAGE. Signals were visualized and analyzed with
a FLA7000 system. The black arrowheads are P-gp or BCRP. Verapamil
and FTC (typical inhibitors of P-gp or BCRP, respectively) were used as
controls. The binding of [125I]-IAAP with P-gp and BCRP was calculated
from standard curve analysis using a FLA7000 Bioimage Analyzer
(Fuji Film, Tokyo, Japan) and Multi-Gauge software (Fuji Film).
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(Table 2).
The calculated half-maximal inhibitory concentration
(IC50) values of telaprevir for each substrate transport
are summarized in Table 3. The values suggested that a
higher concentration (≈30 μmol/L) of telaprevir was re-
quired to elicit 50% inhibition of BCRP-mediated trans-
port compared with that of P-gp-mediated transport
(7 μmol/L). These results suggested that the inhibitory
kinetics of telaprevir on the transporter function of
BCRP and P-gp were likely to be competitive.
Effects of telaprevir on IAAP-binding to P-gp and BCRP
The data mentioned above could not be used to ascer-
tain if telaprevir competed with substrate binding on the
transporters. Thus, we examined the effect of telaprevir
on [125I]-IAAP-binding with P-gp and BCRP by a photo-
affinity labeling experiment to observe the direct compe-
tition of telaprevir with the transporter substrate IAAP.
Telaprevir apparently suppressed [125I]-IAAP-binding
with P-gp in a dose-dependent manner (Figures 3A and
B). In contrast, [125I]-IAAP-binding with BCRP was rela-
tively resistant to telaprevir than that with P-gp, and a
higher concentration of telaprevir was required for the
inhibition of IAAP-binding with BCRP. The calculated
IC50 values were ≈ 17 μmol/L for P-gp and >80 μmol/L
for BCRP (Table 4). Overall, our results revealed that
telaprevir would be a direct competitive inhibitor for P-
gp and BCRP, and that P-gp would be a better target for
telaprevir than BCRP.
Discussion
Telaprevir has been reported to be a substrate and in-
hibitor of P-gp [6]. Recent clinical pharmacokinetic and
pharmacodynamic studies suggested enhanced absorp-
tion of digoxin by inhibition or saturation of P-gp in the
intestine due to telaprevir in the gut [7,8]. Such studiesTable 3 IC50 values of telaprevir on transport activity by
P-gp or BCRP
Substrate IC50 of telaprevir (μmol/L)
P-gp VCR 7
BCRP E1S 30
MTX 31suggested that telaprevir is a substrate and inhibitor of
CYP 3A4 and P-gp in vivo. However, biochemical ana-
lyses are needed to clarify the mechanism of biochemical
interaction between telaprevir and P-gp.
Our previous studies on ABC transporters revealed
that verapamil and TKIs (including imatinib, gefitinib,
erlotinib and sunitinib) are inhibitors of P-gp as com-
petitive inhibitors [13-15]. In addition, we showed that
FTC, certain flavonoids and the TKIs mentioned above
are potential competitive inhibitors of BCRP [12]. In the
present study, we demonstrated that telaprevir is a po-
tential direct inhibitor of P-gp and BCRP. Moreover, to
provide mechanistic insights for understanding the inter-
action between ABC transporters and telaprevir, our ana-
lyses of photoaffinity labeling and kinetics showed, for the
first time, that telaprevir could be a direct competitive in-
hibitor for P-gp and BCRP. In vitro cell-free experiments
showed that the IC50 value of telaprevir-mediated P-gp
inhibition was as low as 7 μmol/L. This concentration
would be reached in the gut after oral administration ofTable 4 IC50 values of telaprevir on [
125I]-IAAP binding
with P-gp or BCRP
IC50 of telaprevir (μmol/L)
P-gp 16.5
BCRP >80
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tively insensitive to telaprevir, and a higher concentration
of telaprevir was required for inhibition of IAAP-binding
with BCRP. The HCV protease inhibitor boceprevir has
also been reported to interact with P-gp and BCRP using a
cellular system [9,19]. However, the inhibitory effect of
boceprevir on P-gp seemed to be very low, and that on
BCRP was shown to be weak (IC50 ≈ 80 μM) in that study.
Combined with the data in the present study, telaprevir
appears to be a strong inhibitor of P-gp, and we hypo-
thesize that intestinal P-gp would be a pharmacological
target for telaprevir.
Similar inhibitory potential of telaprevir on other trans-
porters has been characterized (albeit examined by experi-
mental cellular systems). This characterization has been
mainly on the renal transporters OCT2 and MATE1 with
IC50 values (μmol/L) of 6.4 and 23.0, and hepatic trans-
porters OATP1B1, OATP1B and OCT1, with IC50 values
of 2.2, 36.8 and 20.7, respectively [8]. However, the renal
clearance of digoxin (a P-gp substrate) has been reported
to be similar to that without telaprevir [7]. Hence, the ef-
fect of telaprevir on P-gp activity in the kidney seems to
be minimal. We suspect that the steady-state concentra-
tion of telaprevir in each tissue may be an important factor
modulating the activities of P-gp and other transporters.
Our data revealed that telaprevir-mediated P-gp inhib-
ition would be mediated by a direct competitive mechan-
ism. Hence, the combination of substrate and inhibitor
could make prediction of drug–drug interactions on P-gp
in each setting more difficult. Indeed, many patients suf-
fering from HCV and HIV might be subjected to anti-HIV
drugs and anti-HCV drugs, and many of those antiviral
drugs are known to interact with CYPs and transporter
proteins. Multiple binding sites are suggested on ABC
transporter proteins [18], so a complicated drug com-
bination could cause complex drug–drug interactions by
complicated transporter inhibition mechanism. Thus, de-
tailed analyses for each drug based on cell-free systems
could contribute to better understanding of the mecha-
nisms of drug–transporter interactions, particularly those
in combination chemotherapy.Conclusions
Telaprevir can inhibit P-gp- and BCRP-mediated trans-
port, and P-gp-mediated transport is more sensitive to
telaprevir-mediated inhibition. Our study will be helpful
for theoretical consideration of interactions between in-
testinal P-gp and telaprevir during long-term anti-HCV
chemotherapy.Abbreviations
ABC: ATP-binding cassette; BCRP: Breast cancer resistance protein; IC50:
50% inhibitory concentration.Competing interests
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